March 12th 2025, 1:00pm
By Spencer Feldman
RECKGIST score may predict recurrence in neurofibromatosis type 1 GISTs, potentially guiding treatment decisions, according to study findings.
March 11th 2025, 9:00pm
By Kelly Grosklags
Kelly Grosklags discusses how oncologists can guide patients in shared decision-making while managing expectations following a breast cancer diagnosis.
March 11th 2025, 7:00pm
By Ryan Scott
The first patient has been enrolled in the phase 3 PROSTATE-IQ trial being conducted in men with prostate cancer recurrence following a prostatectomy.
March 11th 2025, 5:00pm
By Sue McCarthy
Life-threatening lung cancer has taught me many valuable lessons and made my new normal so fulfilling.
March 11th 2025, 4:14pm
Vepdegestrant improved progression-free survival in patients with estrogen receptor 1 mutations in advanced ER-positive, HER2-negative breast cancer.
March 11th 2025, 3:38pm
By Alex Biese
JAK inhibitor treatment is associated with a reduction in risk of thromboembolic events for patients with myeloproliferative neoplasms.
March 11th 2025, 1:00pm
Treatment with pimitespib was associated with stable disease in two-thirds of patients with advanced gastrointestinal stromal tumors.
March 10th 2025, 9:00pm
Dr. Joseph Mikhael discusses early signs, treatments and supportive care for multiple myeloma in an interview with CURE.
March 10th 2025, 7:00pm
For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes.
March 10th 2025, 5:00pm
By Mary Sansone
As a cancer survivor, I overcame alcohol addiction and urge others to seek support, safe detox and sobriety to improve their treatment and recovery.
March 10th 2025, 4:00pm
By Dr. Sara M. Tolaney
Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.
March 10th 2025, 3:00pm
By Dr. Debu Tripathy
CURE magazine's outgoing editor-in-chief, Dr. Debu Tripathy, reflects on 18 years of advances in cancer care, the impact of AI and the evolving future of oncology treatment.
March 10th 2025, 1:00pm
Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing mutation testing for treatment decisions.
March 9th 2025, 2:00pm
Circulating tumor DNA may be a prognostic biomarker for relapse and early recurrence detection in resected early-stage biliary tract cancer.
March 8th 2025, 7:00pm
The FDA has approved Stoboclo and Osenvelt to address skeletal issues faced by patients with cancer.
Finding Support in Unexpected Places Through Hereditary Cancer Advocacy
Investigating Personalized Vaccine Use in Kidney Cancer Care
Can Aprepitant Improve Survival for Women With Breast Cancer?
Reuniting a Family After Multiple Cancer Diagnoses